The effect of somatostatin analogs on vitamin D and calcium concentrations in patients with acromegaly

Pituitary

Volumn 17, Issue 4, 2014, Pages 366-373

  Ajmal, Adnan ^a   Haghshenas, Arezoo ^a   Attarian, Shirin ^a   Barake, Maya ^a   Tritos, Nicholas A ^a   Klibanski, Anne ^a   Miller, Karen K ^a   Nachtigall, Lisa B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acromegaly; Bone and mineral; Calcium; Somatostatin analog; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; CALCIUM; COLECALCIFEROL; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOCALCIFEROL; LONG ACTING DRUG; OCTREOTIDE; PARATHYROID HORMONE; PEGVISOMANT; PHOSPHORUS; SHORT ACTING DRUG; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; VITAMIN D; SOMATOSTATIN;

ACROMEGALY; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BRAIN SURGERY; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PREVALENCE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RADIATION EXPOSURE; REMISSION; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; BLOOD; MIDDLE AGED;

ACROMEGALY; ADULT; CALCIUM; FEMALE; HUMANS; MALE; MIDDLE AGED; SOMATOSTATIN; VITAMIN D;

EID: 84904117574     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-013-0514-0     Document Type: Article

References (21)

1. Camanni F, Massara F, Losana O, Molinatti GM (1968) Increased renal tubular reabsorption of phosphorus in acromegaly. J Clin Endocrinol Metab 28(7):999-1005
2. Kamenicky P, Blanchard A, Gauci C, Salenave S, Letierce A, Lombes M, et al (2012) Pathophysiology of renal calcium handling in acromegaly: what lies behind hypercalciuria? J Clin Endocrinol Metab 97(6):2124-2133
3. Shah R, Licata A, Oyesiku NM, Ioachimescu AG (2012) Acromegaly as a cause of 1,25-dihydroxyvitamin D-dependent hypercalcemia: case reports and review of the literature. Pituitary 15(Suppl 1):17-22
4. Bonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L et al (2005) Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 20(10):1837-1844 (Pubitemid 41361885)
5. Fiebrich HB, Van Den Berg G, Kema IP, Links TP, Kleibeuker JH, Van Beek AP et al (2010) Deficiencies in fat-soluble vitamins in long-term users of somatostatin analogue. Aliment Pharmacol Ther 32(11-12):1398-1404
6. Mosekilde L (2005) Vitamin D and the elderly. Clin Endocrinol (Oxf) 62(3):265-281
7. de Boer IH, Levin G, Robinson-Cohen C, Biggs ML, Hoofnagle AN, Siscovick DS et al (2012) Serum 25-hydroxyvitamin D concentration and risk for major clinical disease events in a community-based population of older adults: a cohort study. Ann Intern Med 156(9):627-634
8. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357(3):266-281
9. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(7):1911-1930
10. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B (2006) Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84(1):18-28 (Pubitemid 44699167)
11. Singh RJ, Taylor RL, Reddy GS, Grebe SK (2006) C-3 epimers can account for a significant proportion of total circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and interpretation of vitamin D status. J Clin Endocrinol Metab 91(8):3055-3061 (Pubitemid 44271755)
12. Farrell CJ, Martin S, McWhinney B, Straub I, Williams P, Herrmann M (2012) State-of-the-art vitamin D assays: a comparison of automated immunoassays with liquid chromatography-tandem mass spectrometry methods. Clin Chem 58(3):531-542
13. Mazziotti G, Bianchi A, Cimino V, Bonadonna S, Martini P, Fusco A et al (2008) Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency. Pituitary 11(1):55-61 (Pubitemid 351168085)
14. Wassenaar MJ, Biermasz NR, Hamdy NA, Zillikens MC, van Meurs JB, Rivadeneira F et al (2011) High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol 164(4):475-483
15. McKeage K, Cheer S, Wagstaff AJ (2003) Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 63(22):2473-2499 (Pubitemid 37392914)
16. Cappelli C, Gandossi E, Agosti B, Cerudelli B, Cumetti D, Castellano M et al (2004) Long-term treatment of acromegaly with lanreotide: evidence of increased serum parathormone concentration. Endocr J 51(6):517-520 (Pubitemid 40209017)
17. Legovini P, De Menis E, Breda F, Billeci D, Carteri A, Pavan P et al (1997) Long-term effects of octreotide on markers of bone metabolism in acromegaly: evidence of increased serum parathormone concentrations. J Endocrinol Invest 20(8):434-438 (Pubitemid 27483067)
18. Fredstorp L, Pernow Y, Werner S (1993) The short and long-term effects of octreotide on calcium homeostasis in patients with acromegaly. Clin Endocrinol (Oxf) 39(3):331-336 (Pubitemid 23274432)
19. Bergeim O, Stewart FT, Hawk PB (1914) A study of the metabolism of calcium, magnesium, sulphur, phosphorus, and nitrogen in acromegaly. J Exp Med 20(3):218-224
20. White HD, Ahmad AM, Durham BH, Chandran S, Patwala A, Fraser WD et al (2006) Effect of active acromegaly and its treatment on parathyroid circadian rhythmicity and parathyroid target-organ sensitivity. J Clin Endocrinol Metab 91(3):913-919 (Pubitemid 43357758)
21. Lai JK, Lucas RM, Clements MS, Harrison SL, Banks E (2010) Assessing vitamin D status: pitfalls for the unwary. Mol Nutr Food Res 54(8):1062-1071